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Abstract. Many potential disease modifying therapies have been identified as suitable for clinical evaluation in Parkinson’s
disease (PD). Currently, the evaluation of compounds in phase II and phase III clinical trials in PD are set up in isolation, a
process that is lengthy, costly and lacks efficiency. This review will introduce the concept of a multi-arm, multi-stage (MAMS)
trial platform which allows for the assessment of several potential therapies at once, transitioning seamlessly from a phase
II safety and efficacy study to a phase III trial by means of an interim analysis. At the interim checkpoint, ineffective arms
are dropped and replaced by new treatment arms, thereby allowing for the continuous evaluation of interventions. MAMS
trial platforms already exist for prostate, renal and oropharyngeal cancer and are currently being developed for progressive
multiple sclerosis (PMS) and motor neuron disease (MND) within the UK. As a MAMS trial will evaluate many potential
treatments it is of critical importance that a widely endorsed core protocol is developed which will investigate outcomes and
objectives meaningful to patients. This review will discuss the challenges of drug selection, trial design, stratification and
outcome measures and will share strategies implemented in the planned MAMS trials for MND and PMS that may be of
interest to the PD field.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative
disease for which there are currently no therapies that
delay or stop progression. The disease encompasses
an array of motor and non-motor symptoms which
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have an increasing impact on patients’ and carers’
quality of life.
An estimated 0.85% of the population over 60
years of age is affected by PD in the UK [1, 2]. This
amounted to an estimated annual care cost (direct
and indirect) of D 3.6 billion in 2018 [3, 4]. As both
prevalence and incidence are projected to increase, it
is imperative to develop disease-modifying therapies.
With the ever increasing pace of research,
including in vitro and in vivo screening systems,
advances in virtual drug modelling and bioinfor-
matics approaches, the number of suitable drug
candidates for clinical evaluation as potential disease
modifying therapies is on the rise [5–8].
The development, financing and conducting of a
clinical trial can take many years, creating a bottle-
neck for the clinical evaluation of potential therapies,
particularly in the phase III setting. There is there-
fore a need to adopt an innovative and adaptive
approach that allows for the seamless streamlining
of trials and the testing of multiple hypotheses at
once. One such example is the multi-arm, multi-
stage (MAMS) platform trial design. Most MAMS
trials are phase III trials that allow the evaluation
of multiple therapeutic interventions against a com-
mon placebo arm (multi-arm), with pre-determined
interim assessments that will evaluate safety and effi-
cacy of all interventions (multi-stage). This allows
for the early detection of ineffective treatment arms,
which can then be replaced in favour of other inter-
ventions (Fig. 1). Most importantly, the multi-stage
approach allows for the incorporation of phase II
equivalent findings to be carried forward to the final
phase III results without requiring the initiation of a
separate trial. A MAMS trial is not only quicker and
cheaper than a conventional approach, but also more
efficient as fewer patients are required to come to a
phase III powered conclusion regarding a particular
intervention.
There are many challenges inherent to the imple-
mentation of a platform trial. In PD, eight phase II
trials have provided sufficient evidence of efficacy
for the initiation of eight phase III trials within the
last 10 years. Whilst all phase II studies exhibited
at least a trend towards activity, only one phase III
trial (the ADAGIO study) successfully showed evi-
dence of benefit on its efficacy endpoints (Table 1).
Although it is possible that these drugs were not neu-
roprotective, current outcome measures, trial design
features and patient population heterogeneity may
play a significant role in the ability of trials to show
efficacy of a new treatment.
This review will focus on the challenges ahead
for the implementation of a MAMS platform in PD
including drug selection, trial design, stratification
and outcome measures. Many of these challenges
are not unique to PD and therefore insights from
other diseases that have embarked on this process
will be shared. Here we will particularly focus on
current efforts made in the development for MAMS
trial platforms in motor-neuron disease (MND) and
progressive multiple sclerosis (PMS) as well as one
well established MAMS trial for the investigation of
metastatic prostate cancer (STAMPEDE). Further-
more, we will discuss why common design decisions
such as restriction of study populations to early dis-
ease and lack of stratification should be reconsidered.
MAMS PLATFORM TRIALS: STAMPEDE
AND NEURODEGENERATIVE DISEASES
The STAMPEDE trial is perhaps one of the most
successful examples of a MAMS platform. The pro-
tocol was initiated in October 2005 for men with
poor prognosis prostate cancer who were starting
long-term hormone therapy for the first time. Long-
term hormone therapy was discovered in the 1950s
and since then there had been no new treatments
for men with this stage of disease. In the first ver-
sion of the protocol, 5 new treatments (added to long
term hormone therapy) were evaluated against a con-
trol arm of long-term hormone therapy alone. At the
time of writing (October 2019), more than 11,000
patients had been recruited to the study, and version
number 20 of the protocol had been launched. Over
the last 14 years, the control (standard of care) arm
of STAMPEDE has been adapted and improved 4
times – 3 times due to results emerging from research
arms within STAMPEDE and once from results from
another trial. Over a period of 20 years from the start
of the protocol, STAMPEDE will have evaluated 10
different new treatments. The aim is to evaluate fur-
ther treatments within STAMPEDE until at least 2030
and continue to improve the survival of men with
advanced prostate cancer.
Within the UK, MAMS adaptive platform trials
are being developed for MND and PMS. As with PD,
these initiatives have arisen to address the unmet need
for disease modifying therapies with strong backing
from patients, carers and charitable groups. A MAMS
platform design was selected in both conditions to
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Fig. 1. MAMS trial schematic. In this example, a five year phase III set up is shown that assumes one out of four tested interventions (D)
show a positive signal at an interim analysis after 18 months. By the time one phase III conclusion has been reached, 12 study drugs will
have been initiated into the trial, eight will have been terminated at the interim analysis stage, two will have shown sufficient evidence to be
carried forward to phase III and two will be pending interim results in year six. (--- analysis).
Table 1
The outcome of phase III studies and the phase II studies that preceded them
Phase III studies Clinical Trial Identifier Endpoint met Was there evidence of disease improvement in phase II
Isradipine NCT02168842 Unpublished No, but trend towards efficacy
Inosine NCT02642393 No Yes
Creatine NCT00449865 No Yes
Coenzyme Q10 NCT00740714 No Yes (n = 2)
Yes in advanced disease (n = 1)
Rasagiline NCT00256204 Yes No neuroprotective trials conducted
Ganoderma NCT03594656 Unpublished Unpublished
Pramipexole NCT00321854 No No neuroprotective trials conducted
Levodopa+Carbidopa ISRCTN30518857 No No neuroprotective trials conducted
The MND Systematic Multi-Arm Adaptive Ran-
domised Trial (MND SMART) is being sponsored
by the University of Edinburgh with funding from a
number of charitable organisations and has recently
gained regulatory approval. It takes advantage of
Scotland’s CARE-MND integrated care and research
platform.
For PMS, the UK MS Society Clinical Trials
Network was initiated in 2007 to develop an effi-
cient, multi-arm trial of repurposed drugs. This led
to the development of MS-Secondary Progressive
Multi-Arm Randomisation Trial (MS SMART), a
multi-arm trial evaluating three candidate neuropro-
tective drugs with distinct mechanistic actions [11].
The trial was completed in 2018 with 445 patients
recruited. Although none of the research arms showed
a benefit on the primary phase II outcome (MRI
brain atrophy) over placebo, this trial did demonstrate
the feasibility of conducting a multi-arm trial of this
scale.
The UK MS Society’s 2018-2022 Research Strat-
egy has focused on designing and delivering a clinical
MAMS trial platform to efficiently identify and eval-
uate potential treatments for PMS. It will incorporate
both phase II (interim) and phase III (final) evalua-
tions, with the possibility of dropping arms at interim
stages where there is insufficient signal for efficacy.
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design, outcomes and infrastructure strategic work-
ing groups, a programme grant has been awarded and
the trial will commence setup from early 2020 with
recruitment beginning in 2021.
CHALLENGES TO INITIATING A MAMS
PLATFORM IN PD
The continued failure to discover new medicines
for neurodegenerative diseases reflects bottlenecks
at two pivotal stages of drug development (i)
discovery/identification of promising candidate inter-
ventions and (ii) translation of these agents into
treatments that are available to patients through cost
and time-efficient testing in clinical trials. To max-
imise the potential of a MAMS platform trial which
will run over many years and interrogate many
research questions, it is crucial that there is a pipeline
in place that will continuously identify and evaluate
suitable drug candidates. Furthermore, outcome mea-
sures have to be chosen that are sensitive enough to
changes in disease progression over interim stages as
well as the full duration of the trial. Decisions on out-
come measures, trial population and design need to
be widely endorsed not only in the scientific commu-
nity to encourage widespread collaboration on the
programme, but also by patients as their support is
crucial for success.
Challenge 1: Drug selection
Many diseases have common etiopathological pro-
cesses that are echoed in PD such as inflammation,
protein trafficking and accumulation, oxidative stress
and mitochondrial dysfunction. This is particularly
true for neurodegenerative diseases (Supplementary
Table 1) but can be found across many medical con-
ditions including cancer [9] and diabetes [10]. It
is therefore conceivable that agents targeting these
mechanisms in other diseases may also be of value in
PD.
Drug repurposing is an effective way to identify
new therapeutic strategies as it uses existing clinical
efficacy, safety and regulatory data and if off-patent,
drugs are likely to be quicker and cheaper to get to
licensed approval status.
For the successful implementation of a MAMS
trial platform, a process for the selection of suit-
able drugs needs to be in place. In PD, a process
has been devised through the linked clinical trials
initiative (LCT) [11, 12]. Similar to its predecessor,
the National Institute of Neurological Disorders and
Stroke (NINDS) Committee to Identify Neuroprotec-
tive Agents for Parkinson’s (CINAPS) [13, 14], the
identification and prioritisation of candidates to be
entered into pilot clinical trials for PD is the main
objective of the LCT committee. In short, the process
involves the screening and selection of candidates on
the basis of their potential efficacy in PD, evidence
for safety, ability to penetrate the blood-brain-barrier,
evidence of efficacy in PD animal models, the pos-
sibility for measuring target engagement and their
commercial/patent status. This results in the compi-
lation of detailed dossiers for a subset of drugs that
meet basic pharmacological and safety criteria which
are then scored and presented at an annual meeting of
international experts where prioritisation for clinical
drug testing is finalised [11, 12].
In the MS SMART study, a similar process of sys-
tematic review, commissioned by the MS- Clinical
Trials Network was undertaken of animal and human
trials of putative neuroprotective drugs. This process
included a three-part systematic review and meta-
analysis assessing the neurodegenerative disease
literature including clinical and pre-clinical (animal
and human induced pluripotent stem cell) publica-
tions to identify drugs ranked by a product score
that takes into account efficacy, safety, study size and
quality. The human analysis was extended to other
neurodegenerative diseases including amyotrophic
lateral sclerosis (ALS), Huntington’s, Alzheimer’s
and PD, because of the existence of shared pivotal
pathways in neurodegeneration. The focus of the
upcoming PMS MAMS adaptive platform trial is
on repurposed (already approved drugs) and rescued
drugs (drugs at advanced stage of development but
abandoned before approval) that act on mechanistic
pathways in PMS [15].
MND SMART is utilising the infrastructure
established by MS SMART for drug selection. Addi-
tionally, late-breaking drugs that may not have been
tested previously in neurodegenerative diseases but
show promise from preclinical data or from clini-
cal trials in other diseases with similar underlying
pathological processes are being considered.
Beyond the selection and prioritisation of candi-
date drugs there are other practical considerations that
pose unique challenges to a MAMS trial protocol,
such as the use of a common placebo. Traditionally,
the MAMS trial design allows for the comparison
of multiple therapies against a common control arm.
Whilst this is a useful approach to reduce trial cost,
it makes it difficult to incorporate and compare drugs
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drug candidates initially shortlisted and published by
the LCT in 2013, 11 are available as tablets, 5 as
capsules, 3 as suspension, 3 as injection and 1 as oro-
mucosal spray [12]. Not all placebos are equal and
therefore treatments would either have to be stan-
dardised or an additional placebo arm may have to be
introduced together with drugs using different admin-
istration routes. The latter may negate some of the
efficiency savings anticipated through a MAMS trial
[16].
Challenge 2: Outcome measures
Motor progression
Currently, the Movement Disorder Society -
Unified PD rating scale (MDS-UPDRS) is used
worldwide for the assessment of the severity of PD
symptoms and is endorsed by regulators such as the
FDA. The scale consists of four parts: Parts I and II
– Non-Motor and Motor Experience of Daily Liv-
ing; Part III – Motor Examination; Part IV – Motor
Complications. This revision of the UPDRS rating
scale was introduced in 2008 and aimed to allow finer
differentiation at earlier stages of the disease [17].
Clinical trials have generally utilised either the
clinically assessed part III motor score as their out-
come measure or a composite score of several parts
of the scale. A search of clinicaltrials.gov looking at
neuroprotective trials within the last 10 years shows
that out of 31 phase II studies with a motor outcome,
42% used the part I-III or I-IV total score and 55%
assessed part III only. In contrast, a composite score
is more likely to be used in the phase III setting (out
of eight phase III trials, six utilised a change in I-III
or I-IV composite score as their primary endpoint,
one assessed part III only and one trial did not use
the UPDRS as an outcome measure) [18–25].
However, changes in the MDS-UPDRS total score
(within the first five years of disease) are largely
driven by changes in the MDS-UPDRS Part III score;
as part I and II score changes are not as pronounced
over time [26] their addition into a total score may
reduce sensitivity to change [27]. This is in line
with findings examining the old UPDRS scale [28].
Although several studies have suggested that com-
posite scores are able to detect clinically relevant
differences over time [26, 27, 29], the authors of the
new scale clearly recommended against the use of I-
III composite scores as their unequal factorial loading
reduces sensitivity to change [17].
Assessing part III only has its own limitations: it
provides only a snapshot of the patients’ condition
and is subject to significant inter- and intra- rater vari-
ability, which can undermine score accuracy. This is
especially relevant for large multi-centre trials were
many different raters are assessing patients through-
out the study. Part III results are also dependent on
the medication state of the patient [26, 28, 30] with
OFF state results being more reliable compared with
the ON state [30].
Longitudinal observations of clinical progression
on the rating scale are important in determining the
sensitivity of the scale in detecting differences at
various stages of disease. Whilst some data indi-
cate that overall disease progression up to at least
five years from diagnosis is linear [26, 31, 32], it is
generally accepted that the rate of motor symptom
decline decelerates beyond five years [28, 32–34].
Progression studies using the revised scale are only
just emerging [26, 27, 35]; to date these studies do not
report data of patients beyond five years of disease,
representing an important knowledge gap.
Cognition
Mild cognitive impairment (MCI) affects
20%–33% of patients at diagnosis and 80% of
PD patients will go on to develop PD associated
dementia within 12 years of disease, making
cognitive dysfunction one of the most prevalent
non-motor symptoms of PD [36, 37]. Cognitive
function is thus often monitored in neuroprotective
trials. Progression of cognitive impairment could be
described as inverse to that of motor symptoms, with
slow initial progression for up to 10 years followed
by a rapid decline thereafter [32, 38, 39].
Recent evidence suggests that progression on
the MoCA, MMSE, and Scales for Outcomes in
Parkinson’s disease-Cognition (SCOPA-Cog) in non-
demented PD patients is not reliably detectable over
the typical timeframe of a clinical trial (1 year) [36,
40] with the MoCA being potentially more sensitive
than the MMSE at detecting MCI [37].
Time to event measures
Historically, the most common time to event mea-
sure employed in neuroprotective trials of PD has
been time to initiation of levodopa therapy. A study
published in 2016 showed that 50% of neuroprotec-
tive trials identified at the time investigated time to
initiation of dopaminergic treatment [41]. However,
this measure is highly dependent on the judgement of
the site investigator. In the case of studies where study
drug is withdrawn after commencement of symp-
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to continue the study may also play a role. Time
to commencement of ST is therefore prone to bias.
Other events that signify milestones for disease pro-
gression are onset of dementia, falls, nursing home
placement and death.
Time to falls is of particular interest here as a recent
study suggests that approximately 70% of PD patients
fall within the first 5 years of diagnosis [42] and thus
recording time to first fall may be a relatively rapidly
evolving event in PD in comparison to events that
occur much later such as dementia, nursing home
placement or death.
The choice and feasibility of time to event mea-
sures employed in a clinical trial largely depend on
the patient population being investigated. For exam-
ple, time to death is dependent on the demographic of
patients included in the study [43] with younger onset
patients generally having a lower life expectancy
[44–48], although some studies have found no dif-
ference [49].
Delay of these disease progression milestones are
highly meaningful to patients and may therefore
represent an alternative to conventional primary out-
comes used in phase III trials.
Non-motor symptoms
Progression of non-motor symptoms (NMS) such
as sleep, anxiety, apathy, depression, autonomic
dysfunction and cognition are less influenced by
dopamine therapy and significantly progress over
short periods of 1-2 years even in an early disease
population [50]. This makes measurement of NMS
an attractive tool for evaluating disease progression
in patients that require symptomatic treatment. NMS
in PD can be measured by part I of the MDS-UPDRS
scale or the NMS scale for PD. Both are suitable for
detecting prevalence of NMS within PD populations
[51] and have been used as secondary outcomes in PD
trials. The MDS-NMS has recently been published
[52].
Quality of life measures
Quality of life (QoL) measures are patient reported
outcomes that attempt to measure physical, mental
and social wellbeing that can either be related to
general health or disease specific depending on the
instrument. There are many generic and PD specific
tools available although the most common QoL scale
used in clinical trials of PD is the Parkinson’s Disease
Questionnaire (PDQ-39) which captures the impact
of both motor and non-motor symptoms on quality of
life [53]. The impact of PD on QoL has been reviewed
by others. In summary, PD has a profound impact on
quality of life, has been shown to correlate with dis-
ease severity and has been useful at determining the
impact of symptomatic therapy on patients in early
as well as late disease [53, 54].
Biomarkers
A biomarker is an objectively measured character-
istic that serves as an indicator of normal biological
processes, pathogenic processes or pharmacological
responses to a therapeutic intervention [55]. There is
currently no biomarker that can reliably and sensi-
tively track PD severity [32, 56, 57]. Consequently,
biomarkers are not always measured and if so, they
are generally ancillary exploratory outcomes in PD
trials. Only 11 of 29 published phase II studies
included at least one biomarker measurement in
their protocol. These included 11 studies with brain
imaging assessments [24, 58–64], one assessment
of 8-hydroxy-2’ -deoxyguanosine measurement in
plasma and one in urine [65], as well as two stud-
ies with cerebrospinal fluid (CSF) analysis of protein
aggregation [66, 67]. Progress on the usefulness of
imaging techniques and fluid or tissue biomarkers
has been reviewed extensively by others [56, 57, 68].
Importantly, evidence regarding their relevance to
clinical worsening of the disease is often contradic-
tory.
Digital health technologies (DHT)
DHTs can be broadly categorised into passive
(such as wearables) and active (apps that require data
input or task completion) data capture. Where active
measures are used, compliance may create problems
with accuracy and reliability of data sets over long
study periods [69–72]. Uploading of data collected by
apps and sensors represents an additional challenge,
making studies liable to data gaps due to patients
living in poor network areas or outdated hospital IT
systems. Mobilise-D is an EU funded project that has
set out to improve the accurate assessment of daily
life mobility by developing standardised tools [73]. A
MAMS trial could provide a platform for integrated
assessment of different digital measures that can be
tied in to routinely collected clinical data of disease
progression thereby validating their use.
Shaping future outcomes
The challenge of assessing the neuroprotective
effect of drugs is not unique to PD. Measure-
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progressive condition with relatively short (2–3
years) trials is inherently difficult. In MS there are
also significant variations in progression between
patients and changes in rate over time across several
domains of neurological function. MRI brain atrophy
measurements can be used to quantify aspects of neu-
rodegeneration [74] and have been employed as the
primary outcome in the phase II MS-STAT [75] and
MS-SMART trials, as well as a secondary outcome
in phase III trials of PMS. However, clinical outcome
measures of relevance to patients are critically impor-
tant to determine the functional impact of treatments
on patients with PMS and expected by regulators in
phase III trials.
The Expanded Disability Status Scale (EDSS) is
currently the most widely used scale in phase III PMS
clinical trials. Similar to the UPDRS scale in PD,
where motor function is the main driver of progres-
sion [26], the EDSS overemphasises walking ability,
whilst minimising the contribution of cognition and
arm function [76]. Considering the range of disability
typical of PMS patients, this is a major shortcoming.
To overcome this limitation, the Multiple Sclero-
sis Functional Composite (MSFC) was designed and
includes measures of lower limb function (timed 25-
foot walk), upper limb function and hand dexterity
(9-hole peg test) and cognitive function (Paced Audi-
tory Serial Addition Test) [77]. Subsequent amend-
ments replaced the Paced Auditory Serial Addition
Test by the Symbol Digit Modalities Test, a test of
processing speed, and low-contrast letter acuity as a
measurement of visual function [78]. A composite
outcome measure has been successfully used in the
INFORMS trial [79] and was an exploratory outcome
in the ORATORIO trial (phase III trial of fingolimod
and Ocrelizumab respectively) [80].
In the design of the UK MS Society’s PMS adaptive
trial platform, a composite clinical endpoint, based on
EDSS, 9-hole peg test and timed 25-foot walk, was
decided as the primary phase III outcome based on
expert consensus from the outcomes working group.
As a composite endpoint is reached by confirmed dis-
ability progression on just one of the scales included
in the composite measure, more progression events
are recorded than if just assessing one scale alone,
thereby reducing the time required to reach a progres-
sion endpoint as well as the number of participants
required. It was also favoured by patient and public
interest groups as it encompassed a broader range
of meaningful measurements, particularly in non-
ambulant patients in whom walking tests may not
be possible or relevant.
Composite outcomes have also been successfully
developed for MND. Given the typical trajectory of
the disease, mortality is an important outcome for
MND clinical trials. However, the large sample sizes
and duration required to power such a study makes
this practically challenging.
The most commonly used and best validated tool
is the Amyotrophic Lateral Sclerosis-Functional Rat-
ing Score ALS-FRS(R). The ALS-FRS(R) has the
advantage of assessing a wide range of neurologi-
cal functions including communication, activities of
daily living and mobility [81, 82]. Thus, the com-
bined assessment of function and survival (CAFS)
ranks outcomes based on survival time and change in
ALS-FRS(R) score was developed [83].
Combining endpoints might be a useful strategy in
PD to enable the simultaneous analysis of multiple
equally important endpoints and may serve to give
aspects of the disease, such as cognition, that become
more pronounced at later stages of disease, a greater
weight.
To date only one phase III trial (The NET-PD LS-1
trial) has attempted to measure a one year delay in
cumulative disability using a global statistic measure
combining the Modified Rankin Scale, Symbol Digit
Modalities Test, PDQ-39 Summary Index, Schwab
and England Activities of Daily Living scale, and
ambulatory capacity over a five year period as pri-
mary efficacy endpoint. In addition to the necessity
for long term monitoring of these measures, which
has implications on cost and attrition rates, the tests
and scales employed exhibited slower progression
and higher variability across the study population
than originally anticipated [23].
Challenge 3: Trial design
Inclusion criteria
It is important that the trial design for a MAMS
platform has strategies in place to minimise or
account for patient heterogeneity in terms of disease
severity and rate of progression as this will affect
variance of efficacy outcomes. Almost all phase III
clinical trials conducted within the last 10 years have
restricted recruitment to early, untreated disease for
this reason (Supplementary Table 2). This patient
group is more likely to follow a linear progression
trajectory which makes it easier and more reliable
to compute efficacy endpoints [31] and drug naı̈ve
PD can be modelled more accurately [35]. It is also
considered that this restrictive recruitment strategy
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rioration within affected brain regions may still be
at a redeemable stage [84]. It should be noted here
that the assessment of a drug naı̈ve PD population
requires adjustments in order to account for patients
that initiate dopamine therapy during the course of the
trial. A common strategy is to define the endpoint as
change from baseline to the end of the study duration
or until initiation of dopaminergic therapy. However,
this method treats differential progression as equal
and does not take into account the potential of these
groups responding differently to the study drug.
Limitation of recruitment to early disease has other
disadvantages. Most importantly, unless the treat-
ment effect of a neuroprotective drug is comparable to
symptomatic benefit of levodopa, patients are likely
to require and receive adjunctive dopamine therapy.
Therefore, if no benefit can be detected whilst patients
receive symptomatic therapy, the agent is not going
to have an impact on the patient’s quality of life. Fur-
thermore, early disease trials generally preclude data
collection on efficacy of treatments in later disease
stages and therefore there is no data to support effi-
cacy or safety as disease advances, which will require
further costly trials. Any beneficial effect at later dis-
ease stages, where different neurological systems are
starting to be involved, would be missed by such a
design and exploration of these drugs for PD are most
likely going to be stopped after a negative result in an
early disease group. In fact, one phase II trial of co-
enzyme Q10 stratified patients into early (not treated
with levodopa) and more advanced (PD with wear-
ing off) arms and found a treatment benefit (change in
total UPDRS score) only in more advanced disease
[85]. Although this result came from a very small
study (average of 12 patients per arm) and may rep-
resent the differential sensitivity of the scale at these
two disease stages, a potential beneficial effect in this
patient group could not have been (and was not) cap-
tured in the later phase III trial that focused on early,
untreated disease [19]. These are important consider-
ations that are particularly relevant in the context of
establishing a continuous platform trial where there
is a high throughput of interventions.
Stratification
A trial that allows for the recruitment of de novo
and more advanced PD will require stratification of
patients based on disease severity. However, it might
be possible to further categorise patients into subtypes
that have differential predicted disease progression.
Patients with baseline characteristics of increased
age, male sex, mild cognitive impairment, REM
sleep behaviour disorder and orthostatic hypoten-
sion are more likely to progress faster, whereas
tremor-dominant patients follow a milder disease
course [86–90]. The differences in disease progres-
sion between these clinical subtypes can be very
significant [86]. Progress in practically distinguishing
between PD subtypes has been made by Fereshtehne-
jad et al and Velseboer et al, who have developed
subtype calculators for newly diagnosed patients [87,
91]. Unless these groups are treated as clinically
distinct in trial design, differences in their treat-
ment response will never be detected and thus their
importance as etiologically distinct groups cannot be
verified. However, whether predictions of these sub-
type calculators hold true in longitudinal data sets
remains to be investigated and previous attempts to
verify clinical subtypes in additional cohorts have
pointed towards a lack of reproducibility as well as
instability of identified phenotypes in early disease
populations [92, 93].
Although the reproducibility of clinical subtypes
in additional cohorts is often inconsistent [92], evi-
dence suggests that tremor dominance in particular,
is highly predictive of slower progression on the
UPDRS scale [86–90, 94–96]. This may be due to
the fact that the UPDRS and MDS-UPDRS scale is
weighted towards tremor and an early presentation
of high tremor scores may reduce the probability of
tremor dominant individuals to progress.
PD is complex and multi-factorial and therefore
it might be wise to step back from the single end-
point paradigm of trial design that is based on the
assumption that a population as a whole will respond
and show improvement homogeneously. One way to
acknowledge the complex multifactorial nature of PD
in a MAMS trial without tightening inclusion criteria,
could be to measure and power interim progression
on individuals with low tremor scores only, whilst
ultimate progression for phase III analysis may be
a non- UPDRS based measure. Whether this is a
feasible approach remains to be determined. In the
MND-SMART trial, interim analysis excludes indi-
viduals classified as long survivors in order to reduce
heterogeneity at that point without excluding long
survivors from the trial. The planned inclusion EDSS
range of 3.0–8.0 for the PMS MAMS trial is also
broader than in previous phase III trials (typically 3.5
or 4.0–6.5). Making clinical trials more inclusive has
been emphasised by patient and public involvement
groups. Baseline EDSS will be one of the minimisa-
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Fig. 2. Methodology to investigate disease modification. The
delayed start design is a two period trial design. In period one,
patients are initially randomised into placebo (delayed start) and
treatment arms (early start) at the end of which, the placebo group is
switched to the study drug (period two). Both groups will receive
the study drug for the remaining duration of the trial. Should a
treatment be neuroprotective rather than symptomatic, the early
start group should have a reduced progression rate as compared
to placebo in period one, a significantly improved MDS-UPDRS
score from baseline at the end of period two and an equal or reduced
rate of disease progression in the early start group compared to the
delayed start group in period two. Thus, such a design has three
endpoints [31]. The wash out design is a two period design that
evaluates a global change in the outcome measure of choice from
baseline over a drug administration period and the maintenance of
this change after the study drug is withdrawn (washed out).
Methodology
There are two distinct trial designs that aim to
distinguish between symptomatic and disease modi-
fying effects of a study drug. These are the delayed
start and wash-out design (Fig. 2). Within the past 10
years, four phase III trials have used a delayed start
design, one has employed a wash out design and three
chose to assess beneficial effects without attempting
to distinguish between symptomatic and neuropro-
tective benefits (Table 2). The delayed start design
has been successfully employed by the ADAGIO
study that investigated the MAO inhibitor rasagiline,
which is currently used as a symptomatic treatment
of PD. However, the design has been criticised as
it assumes linearity of disease progression over the
trial period and whilst it may be reasonable to make
such an assumption in a de novo PD patient group,
its feasibility in more advanced disease is question-
able. Furthermore, differential dropout rates between
the two arms have to be imputed. This is particularly
relevant in trials that examine therapies with known
symptomatic effect on a drug naı̈ve patient population
(such as the ADAGIO study), as the need for symp-
tomatic therapy will occur earlier in the delayed start
group resulting in increased drop out.
The delayed start design is an interesting con-
sideration for a MAMS trial design as it already
allows for an interim analysis after period one which
could serve as an interim checkpoint in a multi-arm
trial. A primary outcome measure that is sensitive
enough to detect changes within the relatively short
time scales of period one and two would have to be
chosen.
The wash-out design requires knowledge of the
pharmacology of the drug and thus evaluation of
blood and plasma levels would have to be incor-
porated into the initial phase II component of the
MAMS trial. This ensures that the wash-out period
is long enough to allow for clearance of the drug
from the body so that a persisting benefit there-
after, indicative of its influence on underlying disease
pathology, can be confirmed. The advantage of this
design is that period one is generally longer than
period one of a delayed start design allowing for the
evaluation of potentially slower evolving outcome
measures. However, long duration effects are often
poorly understood and therefore it is hard to conclude
whether a given wash-out period will be sufficient
to preclude long lasting symptomatic benefits. For
example, despite the short half-life of levodopa in
plasma [97, 98] clinical benefits persist much longer
[99, 100]. Thus the results of the ELLDOPA study,
where levodopa treatment led to sustained improve-
ment of the total UPDRS score over a two week wash
out period (indicative of slowed disease progression)
remained inconclusive and were further confounded
by its imaging substudy that showed a decline in

























Trial methodology and endpoints of phase III neuroprotective trials and their preceding phase II trials within the last 10 years; ST, symptomatic therapy
Methodology Endpoint Intervention Phase Clinical trial Treatment duration Comments
identifier
Delayed start 1) Difference in rate of progression
(period 1)
Rasagiline 3 NCT00256204 Period 1: 9 months;
Period 2: 9 months
Allowed 3 months wash in
for slope analyses
2) non-inferiority of slopes
(period 2)
Ganoderma 3 NCT03594656 Period 1: 6 months;
Period 2: 12 months
3) difference in total UPDRS score between
early and delayed (period 1+2)
Pramipexole 3 NCT00321854 Period 1: 6–9 months;
Period 2: 6 months
Levodopa+Carbidopa 3 ISRCTN30518857 Period 1: 9 months;
Period 2: 9 months
Wash out Difference in rate of change from shared
baseline
Inosine 3 NCT02642393 Period 1: 24 months;
Period 2: 3 months
Change from baseline vs each arm Isradipine 2 NCT00909545 Period 1: 12 months;
Period 2: 0.5 months




Period 2: 2 months
None Change from baseline Creatine 3 NCT00449865 60 months
Change from baseline Coenzyme Q10 with Vitamin E 3 NCT00740714 16 months or
initiation of ST
Change from baseline for those receiving ST
vs placebo
Isradipine 3 NCT02168842 36
Futility boundary 70% of placebo group
progression
Creatine and Minocycline 2 NCT00063193 12 months or
initiation of ST
DATATOP placebo + trial
placebo arm
Change from baseline Coenzyme Q10 2 NCT00004731 16 months or
initiation of ST
Futility boundary 70% of placebo group
progression
Coenzyme Q10 2 NCT00076492 12 months or
initiation of ST
DATATOP placebo + trial
placebo arm
Futility boundary 70% of placebo group
progression
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Distinguishing between a symptomatic and a dis-
ease modifying therapy at the interim check point
may be challenging. A MAMS trial is only feasi-
ble if an interim analysis is conducted before the
recruitment target for the phase III element is reached.
Introducing a wash out or delayed start design prior
to the interim analysis may increase the trial dura-
tion beyond the feasibility threshold for a MAMS
trial. Therefore, a MAMS trial design that post-
pones distinguishing between disease modification
and symptomatic effects until the phase III analysis
may be more practical.
PROPELLING MAMS INTO ACTION
A MAMS trial is a substantial logistical undertak-
ing and thus requires significant investment to ensure
trial delivery. STAMPEDE, which has been running
for more than 10 years currently employs tens of core
staff that are responsible for continued data collec-
tion, management, analysis and biobanking, amongst
a range of other roles as well as facilitating the seam-
less introduction of new study arms. Beyond the core
staff required for the trial, which is generally funded
through disease specific charities, funding for indi-
vidual research arms is sourced separately through
standard clinical research grants or industry sponsor-
ship. MAMS trial arms should
1) investigate drugs that are as divergent as possi-
ble (a practical consideration that also retains
the possibility of combining effective treat-
ments at a later stage) and
2) be powered to compare active arms to placebo
only
thereby avoiding direct competition between drugs
making it more appealing to industry and has attracted
industry to the STAMPEDE trial.
Gaining regulatory approval for a seamless phase
II/III design may be perceived as a barrier to
the implementation of an adaptive trial platform.
Although this approach is novel in PD, the Med-
ical Research Council Clinical Trials Unit for the
STAMPEDE trial has a proven track record for the
implementation of adaptive trials within the UK and
have experienced regulators to be open minded and
helpful in the development of adaptive trial proto-
cols. The MND SMART trial has obtained regulatory
approval to commence recruitment in early 2020.
This represents a growing recognition that in situ-
ations where there is an unmet need for effective
therapies, and/or patient populations are limited, such
designs have the potential to facilitate ongoing eval-
uation of drugs over time and are thus worthy of the
considerable effort required for their implementation
and continued adaptation. Selection of the primary
outcomes would need to be made with regulatory
agencies in mind and any adaptations made during
the course of the trial would also need to be aligned
with regulatory requirements.
In order to establish a MAMS trial platform
consensus will have to be reached on 1) drug selec-
tion, 2) an appropriate patient population for study,
3) methodology for identifying disease modifica-
tion and whether this is necessary as well as 4)
effective and relevant outcome measures. Current
phase III studies have been focused on an early PD
patient population and whilst practical considerations
have played a role in dictating this, recent devel-
opment in identification of progression subgroups
as well as the development of composite measures
may open the gate to more inclusive recruitment
strategies.
To reach consensus on these issues in PD, a Del-
phi process is currently being developed to inform
the design of a MAMS platform. This method is
an iterative approach whereby experts from differ-
ent backgrounds such as clinicians, funders, industry,
academics, regulators and patients will be invited to
complete a series of questionnaires reaching consen-
sus over multiple survey rounds.
We propose that the Delphi process should inform
the remit for focused working groups to develop trial
design, outcome measures and trial infrastructure,
thereby ensuring that the wider research community,
as well as patients have the opportunity to engage in
the development of the MAMS platform.
CONCLUSION
A MAMS trial is an excellent platform that gives
the opportunity to simultaneously test the benefit
of multiple agents with the added benefit of inte-
grated interim analyses allowing for the removal of
arms that do not show sufficient evidence of effi-
cacy. To date, clinical investigation of neuroprotective
therapies is hampered by a lack of availability and
consensus around methodology and outcome mea-
sures. By including a broad field of clinical research
stakeholders, as well as patients, it is hoped that
a strategy for implementing a MAMS trial will be
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relevance to patients, thereby giving it the best chance
for success.
Dedicated effort over two years in the MS field,
which has faced similarly complex issues, especially
with regards to outcome measures, has led to a
research grant award for the implementation of their
MAMS trial. This is encouraging and inspires con-
fidence that a similar approach will make a MAMS
trial for PD possible in the near future.
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